Lorven Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 7 Year, 25 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit 533.33%
(FY 2022)
- Ebitda 633.33%
(FY 2022)
- Net Worth 17.33%
(FY 2022)
- Total Assets 319.42%
(FY 2022)
About Lorven Therapeutics
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Laxminarayana Vanaparthi, Appalanaidu Satipidakala, Rahul Peraka, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24110AP2017PTC106873
- Company No.
106873
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Oct 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Srikakulam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lorven Therapeutics?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thakasi Kumar  | Director | 18-Oct-2017 | Current |
| Venkataramana Mudili | Director | 18-Oct-2017 | Current |
| Laxminarayana Vanaparthi | Additional Director | 01-Oct-2021 | Current |
| Appalanaidu Satipidakala | Additional Director | 01-Oct-2021 | Current |
| Rahul Peraka | Additional Director | 01-Oct-2021 | Current |
Financial Performance and Corporate Structure Insights of Lorven Therapeutics.
Lorven Therapeutics Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 533.33% increase in profit. The company's net worth Soared by an impressive increase of 17.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lorven Therapeutics?
In 2022, Lorven Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lorven Biologics Private Limited
Active 9 years 1 monthRahul Peraka and Venkataramana Mudili are mutual person
Seyn Biologics Private Limited
Active 1 year 1 monthRahul Peraka and Venkataramana Mudili are mutual person
Srk Cleanrooms Private Limited
Active 3 years 9 monthsRahul Peraka and Venkataramana Mudili are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lorven Therapeutics?
Unlock and access historical data on people associated with Lorven Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lorven Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lorven Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
